Baxter International Inc. will continue to consider cutting "lower growth, lower margin" businesses, Chief Financial Officer John Greisch said Tuesday. Speculation has swirled recently that Deerfield-based Baxter is shopping its blood-transfusion therapies, a unit with static sales within Baxter's larger bioscience business. Greisch didn't name that business specifically and said Baxter wouldn't cut its core bioscience, medication delivery or renal businesses, but he said "there may be pieces within those businesses that we would look to do something with."
